ArticleGut2020
Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis.
Article in Gut, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
131 citing papers in PubMed, 2 syntheses or guidelines pooled it, 214 citations in OpenAlex.
- Systematic review: microbial manipulation as therapy for primary sclerosing cholangitis.Alimentary pharmacology & therapeutics · 2023Pooled it
- [Guidelines on the diagnosis and management of primary sclerosing cholangitis (2021)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Guideline
- The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease.Journal of hepatology · 2020Trial
- Compositional and functional differences of gut microbiome and metabolome inform pathogenesis of cholestatic liver disease.Gut microbes · 2026Article
- Miniature bioreactor arrays for modeling functional and structural dysbiosis in inflammatory bowel disease.Gut microbes · 2026Article
- Integrated Multi-Omics Reveals Complementary Luminal and Mucosal Host-Microbiome Interactions Associated with Disease Activity and Phenotype in Paediatric Inflammatory Bowel Disease.Microorganisms · 2026Article
- Occurrence and Co-Occurrence of Regulated and Emerging Mycotoxins in Foods Marketed to U.S. Toddlers.International journal of environmental research and public health · 2026Article
- Oral microbiome dysbiosis and oral-gut microbial network disruption in hand osteoarthritis: data from the Xiangya Osteoarthritis Study.RMD open · 2026Observational
- Distinct phenotype of primary sclerosing cholangitis-associated inflammatory bowel disease.Journal of gastroenterology · 2026Review
- Article
- Beyond the Graft: Optimizing Post-Transplant Care in Primary Sclerosing Cholangitis.Journal of clinical medicine · 2026Review
- [Exploring the research on the molecular mechanisms of autoimmune liver diseases].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- The role and possible mechanism of intestinal fungi in the progression of chronic liver diseases.NPJ biofilms and microbiomes · 2026Review
- Ecological patterns of the gut mycobiome and microbiome in ulcerative colitis across life stages.Frontiers in cellular and infection microbiology · 2026Article
- Research progress on the role of gut microbiota dysbiosis in the pathogenesis of immune-mediated liver diseases.Frontiers in immunology · 2026Review
- Serum Anti-<italic>Saccharomyces cerevisiae</italic> Antibody Is Associated with Disease Severity in Patients with Primary Sclerosing Cholangitis.Digestive diseases (Basel, Switzerland) · 2026Article
- Associations and interactions between prokaryotes and other gut biota in non-human primates.Primates; journal of primatology · 2026Review
- Research trends on autoimmune liver diseases and gut microbiota (1989-2025): a bibliometric and visualization analysis based on the web of science core collection database.Frontiers in immunology · 2026Article
- Microbial Modulation of the Gut-Liver Axis in Autoimmune Liver Diseases.Seminars in liver disease · 2025Review
- Gut microbiota and tuberculosis infection: interaction and therapeutic potential.Gut microbes · 2025Review
71 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePatients with primary sclerosing cholangitis (PSC) were previously shown to display a bacterial gut dysbiosis but fungal microbiota has never been examined in these patients. The aim of this study was to assess the fungal gut microbiota in patients with PSC.
designWe analysed the faecal microbiota of patients with PSC and concomitant IBD (n=27), patients with PSC and no IBD (n=22), patients with IBD and no PSC (n=33) and healthy subjects (n=30). Bacterial and fungal composition of the faecal microbiota was determined using 16S and ITS2 sequencing, respectively.
resultsWe found that patients with PSC harboured bacterial dysbiosis characterised by a decreased biodiversity, an altered composition and a decreased correlation network density. These alterations of the microbiota were associated with PSC, independently of IBD status. For the first time, we showed that patients with PSC displayed a fungal gut dysbiosis, characterised by a relative increase in biodiversity and an altered composition. Notably, we observed an increased proportion of
conclusionThis study demonstrates that bacteria and fungi contribute to gut dysbiosis in PSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.